Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Short Interest Update

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 3,850,000 shares, a drop of 8.3% from the December 15th total of 4,200,000 shares. Currently, 6.7% of the shares of the company are short sold. Based on an average trading volume of 606,000 shares, the short-interest ratio is currently 6.4 days.

Insider Activity

In related news, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at $47,547,699.84. The trade was a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 8,253 shares of company stock valued at $1,001,434 in the last quarter. Company insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in JAZZ. Itau Unibanco Holding S.A. bought a new position in Jazz Pharmaceuticals during the second quarter worth $29,000. EverSource Wealth Advisors LLC boosted its stake in Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 97 shares in the last quarter. UMB Bank n.a. boosted its stake in Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 129 shares in the last quarter. GAMMA Investing LLC boosted its stake in Jazz Pharmaceuticals by 41.3% during the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 121 shares in the last quarter. Finally, Venturi Wealth Management LLC boosted its stake in Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after acquiring an additional 704 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

JAZZ has been the subject of a number of recent research reports. Piper Sandler reissued an “overweight” rating and issued a $163.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. TD Cowen cut their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Robert W. Baird boosted their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $177.00.

Jazz Pharmaceuticals Trading Down 1.2 %

NASDAQ JAZZ traded down $1.44 on Friday, hitting $121.18. The company’s stock had a trading volume of 388,542 shares, compared to its average volume of 538,909. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $134.17. The company’s 50-day moving average is $122.78 and its 200 day moving average is $114.67. The firm has a market cap of $7.33 billion, a PE ratio of 17.07, a PEG ratio of 0.88 and a beta of 0.56.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.